In December 2025, Kyverna Therapeutics reported positive Phase II results for its lead CAR-T candidate miv-cel in patients with stiff-person syndrome, driving a 41% share jump over a one-month span. The trial enrolled 24 patients across eight centers in the U.S. and Europe, with 75% achieving a clinically meaningful improvement in mobility scores by week 12, compared with 20% in a historical control cohort. Kyverna highlighted a median reduction of 45% in electromyographic hyperexcitability, a key biomarker for symptom severity. These findings follow a data readout that exceeded both internal projections and consensus estimates from five sell-side analysts, reinforcing confidence in the program’s therapeutic potential and supporting the company’s path toward a pivotal Phase III study slated to begin in mid-2026.

Kyverna has positioned itself at the forefront of one-time immune reset treatments for autoimmune diseases, with lead programs targeting lupus and multiple sclerosis. As of Q3 2025, the company reported a cash runway extending into Q2 2027, bolstered by a $150 million Series C financing closed in October. Year-to-date stock performance stands at a gain of 142%, reflecting strong investor appetite for novel, durable therapies that could displace chronic treatment regimens. Management has reiterated plans to initiate a first-in-human trial in systemic lupus erythematosus by H2 2026, leveraging non-viral delivery technology designed to reduce manufacturing complexity and treatment costs compared with conventional cell therapies.

Analysts at Gabelli Funds and Emerald Advisers project an upside of over 267% based on peak sales models for miv-cel in stiff-person syndrome and lupus, estimating a combined addressable market of $6 billion by 2030. They anticipate strategic partnerships or M&A interest in late-stage 2026 as large biopharma firms seek to bolster their immunology pipelines. However, risks include potential delays at the FDA due to ongoing staff turnover, and the company’s reliance on milestone-based financing agreements that could dilute existing shareholders if clinical progress stalls. Kyverna’s ability to demonstrate durable responses in larger, controlled trials will be critical to sustaining its current valuation trajectory.